CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience™, Invitrogen™

Description

• Description: The DJR1 monoclonal antibody reacts with human DR4, also known as TRAIL-R1
• DR4 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis
• DR4 is expressed by a variety of human tumor cells and at very low level on human leukocytes
• Expression has also been found inside the cell on some cell lines (Zhang et al)
• This has been confirmed with intracellular staining of Jurkat cell line
• Please contact tech@ebioscience.com for more information
• Applications Reported: The DJR1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This DJR1 antibody has been pre-titrated and tested by flow cytometric analysis of human DR4-transfected cells
• This can be used at 5 μL (0.5 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
• Filtration: 0.2 μm post-manufacturing filtered
• TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1
• The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family
• DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues
• Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms
• Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).